Literature DB >> 23281433

Non-Hodgkin lymphoma: the clinician's perspective--a view from the receiving end.

Joseph M Connors1.   

Abstract

Optimal treatment of non-Hodgkin lymphoma depends on establishing an accurate diagnosis and determining the stage or anatomic extent of the lymphoma. With this information, the treating clinician can assign the lymphoma to a subgroup characterized by expected natural history: indolent, aggressive, acute leukemia-like or viral, which generally reflects the typical behavior of the disease unmodified by treatment and indicates the urgency with which intervention must be offered. Finally, a number of special circumstances and problems posed by specific lymphomas must be anticipated and the therapeutic plan altered to accommodate them. After primary treatment, special secondary events such as transformation to more aggressive histologic types must be recognized and the treatment plan must be altered to address these events. This article reviews standard diagnostic grouping of lymphomas, special problems encountered during primary diagnosis and subsequent clinical evolution and emphasizes the cooperative interaction between the hematopathologist and the treating clinician that underlies optimal management.

Entities:  

Mesh:

Year:  2013        PMID: 23281433     DOI: 10.1038/modpathol.2012.184

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  6 in total

Review 1.  Glucocorticoids and Cancer.

Authors:  Miles A Pufall
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

2.  Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

Authors:  Michael L Wang; Kristie A Blum; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Liang Zhang; Linda Baher; Mei Cheng; Dana Lee; Darrin M Beaupre; Simon Rule
Journal:  Blood       Date:  2015-06-09       Impact factor: 22.113

3.  Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients.

Authors:  Olivia Marini; Cecilia Spina; Elda Mimiola; Adriana Cassaro; Giovanni Malerba; Giuseppe Todeschini; Omar Perbellini; Maria Scupoli; Giuseppe Carli; Davide Facchinelli; Marco Cassatella; Patrizia Scapini; Cristina Tecchio
Journal:  Oncotarget       Date:  2016-05-10

4.  The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting.

Authors:  Katherine Antel; Carly Levetan; Zainab Mohamed; Vernon J Louw; Jenna Oosthuizen; Gary Maartens; Estelle Verburgh
Journal:  BMC Cancer       Date:  2019-04-25       Impact factor: 4.430

5.  MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential.

Authors:  Marta Fernandez-Mercado; Lorea Manterola; Charles H Lawrie
Journal:  Curr Genomics       Date:  2015-10       Impact factor: 2.236

6.  Perioperative management of a pregnant patient with mediastinal tumor complicated by tuberculosis.

Authors:  Motoi Kumagai; Wakana Koishi; Hiroya Takahashi; Kenji Suzuki
Journal:  JA Clin Rep       Date:  2017-12-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.